股票 
板块 
用户 
资讯 当一个新药分子从实验室构想奔赴临床，要如何提速闯关、打通研发全链路？上市七载，美迪西给出了属于CRO行业的解法：跳出单一产业链服务节点的局限，搭建起融合源头创新、成果转化、资本助力、AI赋能、人才供给、客户共进的创新生态，构筑开放协同、动态迭代的新药创新生态圈，以多方合力，为新药研发打通从Target到IND的完整通路。
源头
创新
联动科研院所，让创新源头迸发
创新药的萌芽，根植于基础研究的沃土。美迪西持续深化与中国药科大学、上海大学、莆田学院等高校院所的合作，通过教育发展基金、联合课题攻关、定向人才培养等方式，打通基础研究通向产业落地的通道。针对院校项目有技术、缺平台的痛点，美迪西以专业技术服务支持创新药从Target推进至IND申报，让源头创新拥有更顺畅的转化路径。
熟化
转化
牵手院士专家，让成果破壁出圈
源头科研成果想要跨过死亡之谷，还需要专业化平台助推熟化。2022年，美迪西发起成立院士创新药熟化中心，成为浦东首批大企业开放创新中心（GOI）之一。该中心整合新药投融资、一站式研发服务和新药研发交易等平台，为早期项目提供从研发、注册到融资、交易对接的全周期支持，已服务70多家客户，并助力多个院士专家项目获得IND批件，推向产业化的快车道。
资本
活水
链接产业资本，让创新续航有力
早期新药研发既需要技术平台支撑，也离不开持续的资金投入。美迪西与多家金融机构合作，打造新药投融资赋能平台，为新药研发、试验、上市等关键环节提供稳定的资金支持；同时，通过公开、透明的平台机制，助力新药研发阶段性成果的转化与交易。
AI+CRO
融合
携手AI药企，让研发提速增效
AI重塑新药研发范式，但算法产出的虚拟分子，须经合规真实实验验证，方能筛选出有成药潜力的候选分子。美迪西构建“AI干实验智能预测＋一站式合规湿实验验证”的干湿闭环，搭建覆盖核酸、小分子、生物大分子、多肽等方向的MAIDD平台，并搭建NAMs服务平台，赋能新药研发提质增效。
此外，美迪西联合张江集团发起成立张江AI新药研发联盟，与英矽智能、德睿智药、晶泰科技等头部AI药企深度合作，助力其AI新药临床前研发，让智能算法转化为可申报的研发成果。
人才
培育
深化校企共育，让创新薪火永续
生态能否持续运转，核心在于复合型创新人才。美迪西与中国药科大学推动师资互聘与双向交流，共建关键技术攻关联合实验室，联合申报科研项目，举办学术论坛、技术研讨会等活动，培养创新药领域高素质研发人才；同时面向全球引进研发专家，搭建内部技术晋升通道，持续为创新生态注入动能。
此外，美迪西已向中国药科大学、复旦大学、上海大学、莆田学院等高校捐赠，助力药学人才培育与学科建设，为行业长远发展积蓄人才力量。
客户
共进
携手全球伙伴，让创新药扬帆出海
生态圈的最终价值，在于推动创新药从实验室走向临床、从中国走向世界；美迪西依托约2.9万平方米GLP实验室、近1100种动物模型，以及覆盖ADC/AOC、小核酸、多（环）肽、TPD、RIPTAC等新分子技术的服务平台，凭借 NMPA、FDA、OECD等GLP资质，可支持中美欧澳等多国注册申报，现已服务全球 2000余家客户，助力 691 件 IND 获批临床，客户覆盖跨国药企、本土龙头、新兴Biotech及AI药企，让创新走得更远。
七年织就创新生态，美迪西以协同共生赋能新药研发。
上市七周年之际，美迪西正持续扩容开放、协同、迭代的新药创新生态圈，联结科研、资本、技术、人才与产业各方力量，托举更多中国创新药从Target走向IND，从中国走向世界。
关于美迪西
美迪西（股票代码：688202.SH）成立于 2004 年，专注于为全球制药企业、研究机构及科研工作者提供全方位的临床前新药研发服务。公司构建了覆盖药物发现、药学研究至临床前研究的一站式综合研发平台，并在 ADC/AOC、小核酸、多 (环) 肽、TPD、RIPTAC等前沿领域搭建了服务平台。公司建立了符合国际规范的质量体系，已获得中国 NMPA、美国 FDA、欧盟 OECD 等 GLP 认证以及 AAALAC 国际认证。目前，公司在上海和Boston拥有约 9.2 万平方米研发实验室。至 2026 年 6 月末，公司已为全球超 2000 家客户提供药物研发服务，参与研发完成的新药项目已有 近700 件 IND临床批件。美迪西将继续携手国内外合作伙伴共同推动药物创新，为人类健康贡献力量。欢迎访问公司官网 www.medicilon.com.cn 了解更多详情。
7th Anniversary Q&A#4
From Isolated Capabilities to a Symbiotic Ecosystem: How Medicilon Is Building a New Drug Innovation Ecosystem？
How can new drug candidates clear R&D hurdles and advance from lab concepts to clinical trials? Seven years after its STAR Market listing, Medicilon delivers a CRO answer: stepping beyond isolated service nodes to build an open, evolving innovation ecosystem that unites original research, translational maturation, capital support, AI enablement, talent development and client collaboration. Together, these stakeholders enable an uninterrupted Target?to?IND pathway for new drug discovery.
Foundational
Innovation
Partnering with Academic Institutions
Innovative drugs are rooted in fundamental research. Medicilon maintains long?term partnerships with China Pharmaceutical University, Shanghai University, Putian University and other academic institutions. Through research grants, joint projects and tailored talent programmes, we connect basic science with industrial translation. For academic teams with promising ideas but limited infrastructure, Medicilon drives projects from target identification through IND submission, smoothing the path for early innovation.
Translational
Maturation
Working with Leading Experts
Early research outcomes require specialised support to cross the “valley of death”. Launched in 2022, Medicilon Academician Innovative Drug Maturation Center ranks among Pudong’s first Government?led Open Innovation (GOI) centres. It integrates drug financing, end?to?end R&D and licensing services, offering full cycle support for early assets covering R&D, regulatory filing, financing and deal matching. The centre has served over 70 clients and advanced multiple academicians led programmes to secure IND approvals.
Capital
Momentum
Linking Investors to Sustain Innovation
Early drug discovery relies on both technical platforms and continuous funding. Medicilon collaborates with financial partners to create a dedicated biotech financing platform, supporting drug development, testing, and commercialization. Its transparent framework also accelerates licensing and transactions for R&D achievements.
AI+CRO
Integration
Collaborating with AI-Driven Biotechs
AI is reshaping the drug development paradigm, yet virtually designed molecules require compliant wet?lab validation to identify viable candidates. Medicilon runs a closed dry and wet workflow: AI predictive modelling paired with regulated experimental validation. Our MAIDD platform supports small molecules, biologics, peptides and small nucleic acids, complemented by an NAMs service platform to lift R&D efficiency.
Medicilon also co?founded the Zhangjiang AI Drug Discovery Alliance with Zhangjiang Group. We work closely with leading AI drug discovery companies including Insilico Medicine, MindRank and XtalPi, translating their algorithm?generated molecules into preclinical assets ready for regulatory filing.
Talent
Development
Joint University–Industry Cultivation
A resilient innovation ecosystem depends on skilled interdisciplinary researchers. Together with China Pharmaceutical University, Medicilon operates faculty exchanges, joint laboratories, collaborative grant applications and academic symposia to train high?level drug discovery professionals. We also recruit global experts and maintain structured internal career tracks for technical staff.
Medicilon has donated to China Pharmaceutical University, Fudan University, Shanghai University and Putian University to strengthen pharmaceutical education and discipline development, building a lasting talent base for the industry.
Shared Growth with
Global Clients
Taking Innovation Go Worldwide
The ecosystem’s core mission is to bring novel medicines from the lab to patients, across borders. With roughly 29,000 m2 of GLP laboratories, nearly 1,100 animal models, and platforms for emerging modalities such as ADC/AOC, small nucleic acids, cyclopeptide, TPD and RIPTAC, Medicilon holds GLP accreditations from NMPA, FDA and OECD. These credentials support regulatory submissions across China, the US, Europe, Australia and beyond. We have served more than 2,000 global clients and supported 691 IND approvals, spanning multinational pharma, emerging biotechs and AI-driven biotechs.
Over seven years, Medicilon has built this interconnected innovation network to advance drug discovery through collaborative growth. Medicilon continues to expand this open ecosystem, bridging academia, capital, technology, talent and industry to move more new drug candidates from Target to IND and onto the global stage.
About Medicilon
Founded in 2004, Medicilon (Stock Code: 688202.SH) is dedicated to delivering comprehensive preclinical drug R&D services to pharmaceutical enterprises, research institutions, and scientific investigators worldwide. The company has established a one-stop integrated R&D platform encompassing drug discovery, pharmaceutical research, and preclinical research, and has developed service platforms in cutting-edge fields including ADC/AOC, RNAi, peptides (including macrocyclic peptides), TPD, and RIPTAC. The company has instituted a quality system compliant with international standards and has secured GLP certifications from China's NMPA, the U.S. FDA, and the EU's OECD, along with AAALAC International accreditation. At present, the company operates approximately 92,000 square meters of R&D laboratory space across Shanghai and Boston. As of the end of June 2026, the company has provided drug R&D services to over 2,000 clients globally and has supported nearly 700 IND approvals. For more information, visit www.medicilon.com.
评论 (0)